Diversified Trust Co decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,200 shares of the biopharmaceutical company’s stock after selling 805 shares during the period. Diversified Trust Co’s holdings in Regeneron Pharmaceuticals were worth $2,554,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after buying an additional 5,967,733 shares during the period. Wellington Management Group LLP raised its stake in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the period. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 5,121,496 shares of the biopharmaceutical company’s stock valued at $1,984,630,000 after buying an additional 199,975 shares during the period. State Street Corp raised its stake in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock valued at $1,309,861,000 after buying an additional 139,602 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in Regeneron Pharmaceuticals by 2.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock valued at $749,145,000 after buying an additional 41,630 shares during the period. Institutional investors and hedge funds own 66.87% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up 1.66% during midday trading on Wednesday, hitting $505.91. 289,920 shares of the stock were exchanged. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The firm has a 50-day moving average price of $489.80 and a 200-day moving average price of $411.89. The stock has a market cap of $53.41 billion, a P/E ratio of 61.24 and a beta of 1.67.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same quarter last year, the business posted $2.57 earnings per share. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $12.72 EPS for the current fiscal year.
Several research firms have recently issued reports on REGN. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Vetr lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 target price for the company. in a report on Monday, April 24th. UBS AG set a $489.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, May 5th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 14th. Finally, Canaccord Genuity set a $484.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and twelve have issued a buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $457.83.
In related news, major shareholder Sanofi acquired 136,050 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The stock was purchased at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $1,350,000. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,396 shares of company stock valued at $28,484,734. Company insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
